AzTrials
AzTrials

VestibulodyniaNCT05342402

Feasibility Study for Provoked Vestibulodynia

A study testing Somatosensory Rehabilitation Program and Educational Pain Management Program in people with Vestibulodynia, run by Université de Sherbrooke at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The feasibility and acceptability of a somatosensory rehabilitation program and an educational pain management program will be investigated in women with provoked vestibulodynia. Forty-four women will be randomized into the two groups. Read more about this study

Who is it for?
Ages 18 to 45 years, women only
Conditions the study is for
Vestibulodynia
What is being tested?
Somatosensory Rehabilitation Program and Educational Pain Management Program
Could I receive a placebo?
No, everyone receives an active treatment
How many people
45 participants
Where
1 siteCanada
Study dates
16 May 2022to 31 Jul 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • Diagnosis of provoked vestibulodynia according to a standardized gynaecologic exam
  • Moderate to severe pain (≥5/10) located in the vulvar vestibule for at least 90% of vaginal penetrations or attempted vaginal penetrations or activities with pressure on the vagina for at least 3 months

Who cannot join

  • Other causes of vulvo-vaginal pain (e.g. spontaneous vulvovaginal pain not related to sexual intercourse/contact, dermatological condition, herpes, vulvo-vaginal atrophy)
  • Prior vulvo-vaginal surgery or radiotherapy
  • Post-menopausal status
  • Participant refusal to not use other treatments for the provoked vestibulodynia during the entire study (until 3 months post-treatment);
  • Other urogynecological condition (e.g. pelvic organs prolapse ≥3, current urinary/vaginal infection or in the last 3 months)
  • Prior use of Somatosensory Rehabilitation Program or Educational Pain Management Program
Show all 10Show fewer
  • Current or past pregnancy in the last year;
  • Changes of medication that could influence pain perception (e.g. analgesic, antidepressant) in the last 3 months
  • Major psychological condition (e.g. depressive symptoms, anxiety) which can present a security issue for the participant
  • Other medical conditions that could interfere with the study

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • Centre Hospitalier Universitaire de Sherbrooke

    Sherbrooke, Quebec, J1H 5N4

Other trials in Canada

About this study

Official title: Assessing the Feasibility of Somatosensory Rehabilitation and Pain Management Programs in Women With Provoked Vestibulodynia

The feasibility and acceptability of a somatosensory rehabilitation program and an educational pain management program will be investigated in women with provoked vestibulodynia. Forty-four women will be randomized into the two groups. The secondary objective is to explore the effects of the somatosensory rehabilitation program compared to the pain management program. Each participant will receive 12 weekly sessions with a physiotherapist.

The somatosensory rehabilitation program includes minimizing contact with the painful zone of the vulva and uses repeated tactile stimulation at a tolerated distance, proximal to the vulva. The pain management program includes teaching participants about vulvar hygiene, chronic pain mechanisms, relaxation techniques, and approaches to reduce skin irritations in painful regions. Participants in both groups will also receive advice on sexual function and steps toward resuming sexual activities with vaginal penetration.

Read more

Feasibility and acceptability outcomes will be assessed and analyzed using descriptive statistics for the adherence rates to treatment sessions and home exercises, the recruitment rate, retention rate, satisfaction, and adverse effects. The results will be compared to predetermined thresholds to determine the feasibility and acceptability of a future clinical trial.

Secondary measures will be assessed at baseline, two weeks after the treatment, and at three months follow-up. These outcomes will be assessed using validated questionnaires (pain, sexual function, global impression of change, psychological variables, quality of life) as well as evaluations of tactile and pressure sensitivity in vulvar regions using monofilaments, a 2-point aesthesiometer and an algometer. Linear mixed models for repeated measurements (2 groups, 3 measurement times) will be used to explore the treatment effects and will contribute to determining the feasibility of a future clinical trial.

Hypothesis and expected results: It is expected that both programs will meet the pre-determined criteria for acceptability and feasibility in women with provoked vestibulodynia. This study will provide guidance for a future randomized clinical trial.

Conditions
Vestibulodynia
Being tested
Somatosensory Rehabilitation Program, Educational Pain Management Program
Keywords
Provoked Vestibulodynia, Pain, Allodynia, Somatosensory Rehabilitation
Medical subject headings
Vulvodynia, Pain, Hyperalgesia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Somatosensory Rehabilitation ProgramOther

    Somatosensory rehabilitation program includes minimizing contact with the painful zone of the vulva and uses tactile stimulation at a tolerated distance from the vulva. Each participant will also receive advice on resuming sexual activities with vaginal penetration.

  • Educational Pain Management ProgramOther

    Educational Pain Management Program includes education on decreasing irritative contacts with the vulva and relaxation techniques. Each participant will also receive advice on resuming sexual activities with vaginal penetration.

Study groups in NCT05342402
Study groupRoleWhat they receive
Somatosensory Rehabilitation ProgramExperimentalIncludes minimizing contact with the painful zone of the vulva and uses tactile stimulation at a tolerated distance from the vulva. Each participant will also receive advice on resuming sexual activities with vaginal penetration.
Receives: Other: Somatosensory Rehabilitation Program
Educational Pain Management Program (PMP)Active comparatorIncludes education on decreasing irritative contacts with the vulva and relaxation techniques. Each participant will also receive advice on resuming sexual activities with vaginal penetration.
Receives: Other: Educational Pain Management Program

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Adherence rate to home exercises

    The adherence rate to home exercises for each treatment group will be assessed using a daily diary. The participants will record the frequency and duration of the exercises completed.

    Measured: From first to last session (baseline to 12th week)

  2. Patients' adherence rate to treatment sessions

    The patients' adherence to treatment sessions will be recorded in the participants' treatment files (present vs absent).

    Measured: From first to last session (baseline to 12th week)

  3. Adherence rate to assessment sessions

    The adherence to assessment sessions (present vs absent) will be recorded in the participants' assessment files. The reasons for absences will be documented.

    Measured: Baseline to 3 months post-treatment evaluation

  4. Retention rate

    The retention rate will be assessed by calculating the ratio of participants who stay in the study until the post-intervention and 3-month follow-up assessments. Reasons for dropouts will be collected.

    Measured: Baseline to 3 months post-treatment evaluation

  5. Recruitment rate

    The recruitment rate will be recorded as the average number of participants recruited per month as well as the participant accrual rate (participants enrolled / participants screened for diagnosis). Reasons for refusing to participate will be documented if the participant consents to inform the study's research team.

    Measured: At baseline only (during the recruitement period)

  6. Therapists treatment adherence

    The therapists' treatment adherence will be assessed within the therapists' files to verify that all the interventions' key components were applied and respected.

    Measured: From first to last session (baseline to 12th week)

Secondary outcomes (19)
  1. Intervention Acceptability Questionnaire

    The Intervention Acceptability Questionnaire explores the participants' acceptability of the interventions. This questionnaire consists of 4 items measured on a VAS scale (Minimum value: 0; Maximum Value: 10). Each item is analyzed separately, with a greater score meaning higher acceptability of the intervention. This outcome measure will contribute to identifying factors limiting the acceptability of each program.

    Measured: At 2-week post-treatment and at 3 months post-treatment

  2. Credibility and Expectancy Questionnaire

    The Credibility and Acceptability Questionnaire explores the credibility and the participants' expectancy for the interventions. This questionnaire consists of 3 items: two items are measured on a 9-point Likert scale (Minimum value: 1; Maximum Value: 9) and one item is measured in percentages (Minimum: 0, Maximum: 100%). Each item is analyzed separately, with a greater score meaning higher credibility.

    Measured: At baseline only (before the initiation of the treatment)

  3. Patients' Global Impression of Change and Satisfaction

    These two items will determine patient self-reported improvement and satisfaction regarding the effects of the intervention on pain (Patient's Global Impression of Change and Satisfaction). The Patient's Global Impression of Change contains two items that address change in pain and quality of sexual life. It is assessed on a 7-point scale ranging from "very much worse" to "very much improvement". The Satisfaction will be assessed with a single item on an 11-point Likert scale (Minimum: 0, Maximum: 10). A greater score means higher satisfaction. This outcome measure explores the acceptability of the interventions by assessing the extent to which the intervention is perceived as likely to achieve its purpose.

    Measured: At 2-week post-treatment and 3 months post-treatment

  4. Self-Efficacy Question

    A single item included in the participant's diary will assess at which point the participant feels she is confident and self-sufficient in being able to apply the exercises and advice. This item is measured on a VAS scale (Minimum: 0, Maximum: 10) with a greater score meaning higher confidence in being self-sufficient in applying the exercises and advice. This outcome measure will explore self-efficacy regarding the interventions.

    Measured: At baseline, 6 week after the initiation of treatment, and at the last treatment (12th week)

  5. Adverse events

    The adverse events will be noted in the participant's daily diary and in the treatment files.

    Measured: 2-week and 3 months post-treatment

  6. Pain intensity during intercourse (Numerical Rating Scale)

    Pain during intercourse will be assessed using a numeric rating scale (NRS) ranging from 0 to 10, where 0 is no pain at all, and 10 is the worst pain ever.

    Measured: Changes from pre- to 2-week post-treatment, from 2-week post-treatment to 3-month post-treatment, and from pre-treatment to 3-month post-treatment

  7. Pain quality (McGill-Melzack questionnaire-short form)

    The McGill-Melzack questionnaire- short form consists of 15 items that assess the sensory, affective and evaluative components of pain. Items are scored on a 4-point scale with the endpoints (0) no pain at all and (3) severe pain. Minimum value: 0, Maximum value: 45, with more elevated scores meaning higher pain.

    Measured: Change in the scores from pre- to 2-week post-treatment, from 2-week post-treatment to 3-month post-treatment, and from pre-treatment to 3-month post-treatment

  8. Vulvar sensitivity

    Gradual pressure (1 to 1000 g) will be applied to three distinct points of the vestibule at the 3, 6 and 9 o'clock positions. Each of these pressure points will be applied randomly (e.g. 3,6,9 or 3,9,6 or 6,9,3.). During this procedure, each participant will be asked to indicate when they start to feel pain (pain threshold) and subsequently the maximal pressure that can be tolerated (pain tolerance). A higher result means a more elevated pain threshold and a higher pain tolerance.

    Measured: Change in the scores from pre- to 2-week post-treatment, from 2-week post-treatment to 3-month post-treatment, and from pre-treatment to 3-month post-treatment

  9. Vulvar tactile allodynia area

    A force of 15g will be applied using a monofilament in the vulvar region in order to outline the borders of the allodynia (hypersensitivity to tactile stimuli) surface. The width and length of the surface will be measured with a graduated cotton swab (ruler). The surface will be computed by multiplying its width by its length (squared centimeters). This method of assessing allodynia severity is described within the Somatosensory Rehabilitation Method Handbook. A higher value indicates a greater area with tactile allodynia.

    Measured: Change in the surface from pre- to 2-week post-treatment, from 2-week post-treatment to 3-month post-treatment, and from pre-treatment to 3-month post-treatment

  10. Vulvar tactile alllodynia severity

    A series of seven monofilaments (0.02g, 0.4g, 0.7g, 1.5g, 4.0g, 8.0g, 15.0g) will be applied to the outside border of the vulvar vestibule to find the smallest force that causes an increase in pain. This method of assessing allodynia severity is described within the Somatosensory Rehabilitation Method Handbook. A lower result indicates more severe allodynia.

    Measured: Change in the surface from pre- to 2-week post-treatment, from 2-week post-treatment to 3-month post-treatment, and from pre-treatment to 3-month post-treatment

  11. Vulvar tactile sensibility

    Once the allodynia has resolved, the smallest perceived force will be measured by applying monofilaments in a decreasing order (force) to the outside border of the vulvar vestibule (Max: 29g; Min: 0.005g). A lower force value indicates better tactile sensibility.

    Measured: Change in the surface from pre- to 2-week post-treatment, from 2-week post-treatment to 3-month post-treatment, and from pre-treatment to 3-month post-treatment

  12. Two-point discrimination test

    The two-point discrimination test assesses an integrative aspect of tactile sensibility. Once the allodynia has resolved, a 2-point stainless steel aesthesiometer will be applied with one point on the vulvar vestibule border and the other point outside this area. It will be applied at variable and decreasing distances. The result is the smallest distance between the two points at which the person can discriminate if one or two points are being applied (Minimum: 1mm, Maximum: 100mm). A smaller value suggests tactile perception of a higher quality.

    Measured: Change in the surface from pre- to 2-week post-treatment, from 2-week post-treatment to 3-month post-treatment, and from pre-treatment to 3-month post-treatment

  13. Female Sexual Function Index (FSFI)

    The Female Sexual Function Index (FSFI) is a multidimensional measure of sexual function evaluating desire, arousal, lubrication, orgasm, satisfaction and pain. This 19-item questionnaire explores changes in sexual function with a Likert scale ranging from 0 (or 1) to 5. The overall score has a minimum value of 2 and a maximum value of 36. Lower scores mean worse outcomes (low sexual function).

    Measured: Change in the scores from pre- to 2-week post-treatment, from 2-week post-treatment to 3-month post-treatment, and from pre-treatment to 3-month post-treatment

  14. Female Sexual Distress Scale (FSDS)

    The FSDS 13-item questionnaire explores sexually related personal distress in women. Each item is assessed on a 5-point Likert scale from 0 (never) to 5 (always). The total score ranges from a minimum value of 0 to a maximum value of 100. Higher scores mean worse outcomes (greater sexually related distress).

    Measured: Change in the scores from pre- to 2-week post-treatment, from 2-week post-treatment to 3-month post-treatment, and from pre-treatment to 3-month post-treatment

  15. Pain Anxiety Symptoms Scale (PASS-20)

    The PASS-20 is a 20-item questionnaire that explores fear and anxiety responses specific to pain. Each item is assessed on a 6-point Likert scale from 0 (never) to 4 (always). The total score ranges from a minimum value of 0 to a maximum value of 52. Higher scores mean worse outcomes (greater fear of pain).

    Measured: Change in the scores from pre- to 2-week post-treatment, from 2-week post-treatment to 3-month post-treatment, and from pre-treatment to 3-month post-treatment

  16. Pain Catastrophizing Scale (PCS)

    Pain catastrophizing will be assessed using the PCS, which consists of 13 items measuring exaggerated negative thoughts and feelings about the meaning of pain. Items are scored on a 5-point scale with the endpoints (0) not at all and (4) all the time. Minimum value: 0, Maximum value: 52, higher scores mean worse outcomes (greater pain catastrophizing).

    Measured: Change in the scores from pre- to 2-week post-treatment, from 2-week post-treatment to 3-month post-treatment, and from pre-treatment to 3-month post-treatment

  17. Beck Depression Inventory questionnaire (BDI-II)

    Depression or depression symptoms will be measured with the Beck Depression Inventory-II (BDI-II). The BDI-II is comprised of 21 items, with scores for most items ranging from 0 (low intensity) to 3 (high intensity). The maximum total score is 63. Scores above 10 meet the threshold for depression. Higher scores mean more severe depression.

    Measured: Change in the scores from pre- to 2-week post-treatment, from 2-week post-treatment to 3-month post-treatment, and from pre-treatment to 3-month post-treatment

  18. Vaginal Penetration Cognition Questionnaire (VPCQ)

    The VPCQ is a 40-item questionnaire that assesses cognitions regarding vaginal penetration in women. Items are scored on a 6-point scale with the end points (0) never and (6) always. Five aspects of vaginal penetration cognition are assessed: control cognitions, catastrophic and pain cognitions, self-image cognitions, positive cognitions, and genital incompatibility cognitions. Higher scores show higher levels of perceived penetration control.

    Measured: Change in the scores from pre- to 2-week post-treatment, and from pre-treatment to 3-month post-treatment

  19. 12-item Short Form Survey (SF-12 v2)

    The SF-12 questionnaire assesses the impact of health on an individual's everyday life and quality of life. The second version of the SF-12 will be used. Scores range from 0 (minimum) to 100 (maximum). Higher scores indicate better physical and mental health.

    Measured: Change in the scores from pre- to 2-week post-treatment, from 2-week post-treatment to 3-month post-treatment, and from pre-treatment to 3-month post-treatment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Apr 2022
  2. Study start16 May 2022
  3. Primary completion31 Jul 2023
  4. Study completion31 Jul 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Baseline evaluation - Randomization to Somatosensory Rehabilitation Program or Educational Pain Management Program (12 sessions within 12 weeks) - 2 weeks post-treatment evaluation - 3 months follow-up
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
45 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05342402
Sponsor's protocol ID
#2022-4357
Status last verified
Sep 2023
First submitted
16 Apr 2022
Last updated
28 Sep 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Somatosensory Rehabilitation Program and Educational Pain Management Program in people with Vestibulodynia, run by Université de Sherbrooke at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Adherence rate to home exercises (time frame: From first to last session (baseline to 12th week)). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in